OmniAb, Inc. (OABI) SEC Filings & Earnings Calls

Dependence on milestone revenue for growth; sustainability uncertain.

“Revenue increase driven primarily by milestone revenue.”

Legacy small-molecule program discontinuation led to impairment.

“$2.9 million non-cash impairment related to discontinuation of certain legacy small-molecule ion channel programs.” · word for word

Dependence on partner success and information

“Our business metrics are subject to risk and uncertainties related to our dependence on our partners providing timely and accurate information, which impacts our ability to objectively and accurately characterize the current level of activity for each program.” · word for word

Warrants out of the money limit financing flexibility

“As of the date of this report, our warrants are 'out of the money,' which means that the trading price of the shares of our common stock underlying our warrants is below the $11.50 exercise price of the warrants. For so long as the warrants remain out of the money, we do not expect warrant holders to exercise their warrants.” · word for word

Revenue concentration in milestones

“License and milestone revenue fluctuates depending on the timing of new license agreements with partners and partners’ achievement of milestones. Because of these factors, license and milestone revenue could fluctuate significantly from period to period.” · word for word

Limited cash runway

“As of March 31, 2026, our cash, cash equivalents and short-term investments were $49.1 million. We believe our existing cash... are sufficient to support operations through at least the next 12 months.” · word for word

Revenue lumpiness from milestones

“License and milestone revenue fluctuates depending on the timing of new license agreements with partners and partners’ achievement of milestones.” · word for word

Dependence on partner success

“We do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform.” · word for word

Dependence on partner milestones for revenue; cash burn remains significant.

“Revenue surge driven by milestone revenue; net loss still $7.7M; cash guidance $33-38M year-end.”

Significant net loss and cash burn; expects cash to decline to $30M-$35M by end of 2026.

“Net loss $64.8M in FY2025; expects cash to end 2026 at $30M-$35M.”

Revenue decline in FY2025 due to lower license and milestone revenue.

“Revenue decreased from $26.4M to $18.7M.”

Revenue concentration on milestone payments and small molecule programs creates volatility.

“Revenue decline primarily related to lower milestone revenue and completion of small molecule ion channel programs.”

Continued net losses and cash burn despite cost reductions.

“Net loss of $16.5M in Q3 2025; cash use expected to be lower than 2024 but still significant.”

Revenue concentration and volatility

“License and milestone revenue decreased primarily due to a $1.0 million decline in milestone revenue.” · word for word

Dependence on partner success

“We do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform.” · word for word